MSB 0011359C

Drug Profile

MSB 0011359C

Alternative Names: M-7824; MSB0011359C

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator EMD Serono
  • Class Antineoplastics; Bispecific antibodies; Recombinant fusion proteins
  • Mechanism of Action CD274 antigen inhibitors; Transforming growth factor beta modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 29 Nov 2016 Interim adverse events, efficacy, pharmacokinetics and pharmacodynamics data from a phase I trial in Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
  • 01 Mar 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in Germany (IV) (NCT02699515)
  • 01 Aug 2015 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (IV) (NCT02517398)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top